Research Article
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection
Table 1
Demographic information and baseline characteristics.
| | All (n = 54) | CHC (n = 39) | CIR (n = 15) | Statistics | |
| | Age (years) | 42.5 ± 10.4 | 40.1 ± 10.0 | 49.3 ± 8.4 | 3.066 | 0.003 | | Sex (male/female) | 40/14 | 32/7 | 10/5 | 0.727 | 0.394 | | BMI (kg/m2) | 23.0 ± 4.0 | 22.6 ± 3.6 | 24.2 ± 4.7 | 1.286 | 0.205 | | Decompensated cirrhosis | 6 (11.1%) | 0 (0%) | 6 (40.0%) | — | — | | Genotype (3a/3b/6a) | 10/12/32 | 8/4/27 | 2/8/5 | 10.789 | 0.005 | | HCV RNA (log10 IU/mL) | 6.29 ± 0.89 | 6.33 ± 0.81 | 6.17 ± 1.11 | 0.988 | 0.328 | | ALT (IU/L) | 91.6 ± 68.0 | 99.6 ± 75.6 | 70.0 ± 35.1 | 1.841 | 0.072 | | TBil (μmol/L) | 13.8 ± 7.4 | 11.2 ± 4.6 | 20.3 ± 9.4 | 3.306 | 0.005 | | Alcohol addiction | 16 (29.6%) | 9 (23.1%) | 7 (46.7%) | 1.871 | 0.171 | | Route of infection | | | | 1.132 | 0.568 | | Transfusion | 8 (14.8%) | 5 (12.8%) | 3 (20.0%) | | | | IDUs | 16 (29.6%) | 13 (33.3%) | 3 (20.0%) | | | | Unknown | 30 (55.6%) | 21 (53.8%) | 9 (60.0%) | | | | HBV coinfection | 7 (13.0%) | 4 (10.3%) | 3 (20.0%) | 0.253 | 0.615 | | Duration from diagnosis to treatment (months) | 40.2 ± 64.4 | 35.0 ± 60.9 | 54.1 ± 73.5 | 0.943 | 0.351 | | Follow-up (weeks) | 46.1 ± 23.5 | 44.2 ± 22.5 | 51.4 ± 26.2 | 0.988 | 0.328 |
|
|
CHC: chronic hepatitis C; CIR: cirrhosis; BMI: body mass index; ALT: alanine aminotransferase; TBil: total bilirubin; IDUs: intravenous drugs users.
|
